Form 483

Galentic Pharma (India) Private Limited Form 483, 2017-02-24

FDA issued a Form 483 to Galentic Pharma (India) Private Limited on 2017-02-24 with 12 public-safe observations.

483· Form 483 issuedHuman Drugs12 observations

Galentic Pharma (India) Private Limited · Gandhidham, India · Issued February 24, 2017

Overview

  • 12 public-safe observations are available for this inspection.
  • 9 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 Feb 2017
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Ivy E Sweeney

24 Feb 2017
21 CFR 211.101(b)

Measured components for manufacturing

Cited by Ivy E Sweeney

24 Feb 2017
21 CFR 211.134(a)

Correct labels during finishing operations

Cited by Ivy E Sweeney

24 Feb 2017
21 CFR 211.160(a)

Deviations from laboratory control requirements

Cited by Ivy E Sweeney

24 Feb 2017
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Ivy E Sweeney

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations3x
21 CFR 211.160(a)Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.101(b)Cited across public-safe Form 483 observations1x
21 CFR 211.134(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.188(b)(8)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 12 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere